Status: Recruiting
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: O&D BioTech Group CO., LimitedUpdated: Jan 27, 2026Locations: 1
Eligibility criteria
Aged 18-75 years, inclusive, regardless of gender. [+20]
Prior treatment with CAR-T/TCR-T/TIL or other cell therapies; known history of a... [+15]